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Abstract
Background: The National Lung Screening Trial (NLST) demonstrated that in current and former smokers aged 55 to 74
years, with at least 30 pack-years of cigarette smoking history and who had quit smoking no more than 15 years ago, 3
annual computed tomography (CT) screens reduced lung cancer-specific mortality by 20% relative to 3 annual chest X-ray
screens. We compared the benefits achievable with 576 lung cancer screening programs that varied CT screen number and
frequency, ages of screening, and eligibility based on smoking.
Methods and Findings: We used five independent microsimulation models with lung cancer natural history parameters
previously calibrated to the NLST to simulate life histories of the US cohort born in 1950 under all 576 programs. ‘Efficient’
(within model) programs prevented the greatest number of lung cancer deaths, compared to no screening, for a given
number of CT screens. Among 120 ‘consensus efficient’ (identified as efficient across models) programs, the average starting
age was 55 years, the stopping age was 80 or 85 years, the average minimum pack-years was 27, and the maximum years
since quitting was 20. Among consensus efficient programs, 11% to 40% of the cohort was screened, and 153 to 846 lung
cancer deaths were averted per 100,000 people. In all models, annual screening based on age and smoking eligibility in
NLST was not efficient; continuing screening to age 80 or 85 years was more efficient.
Conclusions: Consensus results from five models identified a set of efficient screening programs that include annual CT lung
cancer screening using criteria like NLST eligibility but extended to older ages. Guidelines for screening should also consider
harms of screening and individual patient characteristics.
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Introduction
In the National Lung Screening Trial (NLST) [1], participants
aged 55–74 years randomized to three annual CT examinations
experienced a 20% reduction in lung cancer mortality at 6.5 years
of follow up (16% at 7.5 years) [2], compared to participants
randomized to receive three annual chest radiographs. The NLST
was designed to determine the efficacy of CT screening, but the
eligibility criteria and the number of screens offered were not
meant to represent a population screening strategy. Multiple
clinical guidelines, however, recommend lung cancer screening for
individuals meeting the NLST eligibility criteria [3,4]. Other
guidelines expanded recommendations for screening to individuals
who would have been ineligible for the NLST [5–7].
The NLST provided no direct evidence of further reductions in
lung cancer mortality from additional screens, or of potential
benefits of screening individuals with lighter smoking histories
(fewer than 30 pack-years of cigarette smoking or former smokers
who had quit more than 15 years prior) or individuals younger
than 55 or older than 74 years at the beginning of screening.
We extrapolated the findings of the NLST and compared
various screening programs if adopted in the US population. Five
modeling groups used independent approaches to combine
multiple sources of data to simulate the underlying natural history
of lung cancer and to estimate the benefit of alternative screening
programs. In a single cohort of people born in 1950, each model
estimated the benefits from 576 screening programs that varied
eligibility criteria and frequency of screens, and two reference
scenarios. We sought to rank programs according to a measure of
efficiency, to reduce the number of programs that would require
closer evaluation. The 1950 birth cohort was selected because they
reach age 63 (about mid-range of participants in the NLST) in
2013. When independent models reach consensus on the
characteristics of efficient screening programs, as reported here,
the results can better inform screening guidelines. As in prior
comparative modeling studies of important public health questions
[8,9] independent modeling groups collaborated, sharing inputs
and standardizing analyses to remove uncertainty due to
incongruent modeled populations, endpoints and metrics.
Methods
Models
The microsimulation models used were developed independently
by investigators at five institutions funded by the National Cancer
Institute’s Cancer Intervention and Surveillance Modeling Network
(CISNET, www.cisnet.cancer.gov) consortium through a peer-
reviewed, cooperative award (2010–2015) from the National
Institutes of Health: Erasmus MC in the Netherlands (Model E),
Fred Hutchinson Cancer Research Center (Model F), Massachusetts
General Hospital (Model M), Stanford University (Model S) and the
University of Michigan (Model U). Additional investigators (see also
Acknowledgments) collaborated to develop common inputs and
standardizeanalyses.Theanalysesandresultsdescribedinthisreport
were part of a project to inform recommendations for lung cancer
screening issued by the US Preventive Services Task Force [10].
Each of the five models simulated the underlying natural history
of lung cancer, including dose-response modules that relate an
individual’s detailed, dynamic cigarette smoking history to lung
cancer risk (by histology and sex), and estimated (as an output) the
effect of early detection with CT screening on lung cancer survival
(Table 1, Part A in File S1, and Table S1 in File S1). Algorithms
for following up a positive screening test (defined in our analysis as
suspicious for lung cancer) were simulated with varying detail
(Table 1). Prior to this analysis, all models were populated with de-
identified trial participant histories and adjusted to match the trial
design (e.g., numbers of screens and screening modality). All
models were calibrated to reproduce multiple endpoints consistent
with NLST and the Prostate, Lung, Colorectal and Ovarian
(PLCO) [11] cancer screening trial [12]. Because the models
simulate the natural history of disease, they can predict outcomes
in years after the last year of observed follow up and in what-if
scenarios with hypothetical screening programs and participants.
Common Model Inputs
Publicly available data were used for this analysis. All models
simulated US men and women (all races) born in 1950. Detailed
smoking histories (including non-smokers) and non-lung-cancer
mortality risks were created as described below and in Part C in
File S1, and Figures S1 and S2 in File S1, and used by all models
as common inputs. Smoking histories and quit rates that were
previously estimated through 2000 [13] were updated to calendar
year 2009 for this analysis [14] and years past 2009 were
projected; similarly, tables of non-lung-cancer mortality rates
specific to smoking history (i.e., categories of current smokers had
increased risks relative to never smokers, with former smoker
mortality interpolated as a function of years since quitting) [15])
were updated to 2009 and projected past 2009. (The proportion of
the 1950 cohort that had accumulated the specified number of
pack-years by a given age is shown in Figure S4 in File S1.) In the
NLST and the PLCO trial, individuals had substantially lower
non-lung cancer mortality than the general population even after
adjusting for their smoking status. Our use of US population
other-cause mortality rates rather than the lower rates observed in
the NLST or PLCO was based on an assumption that the ‘‘healthy
volunteer’’ effect in the trials would not persist if screening for lung
cancer disseminated widely.
Standardized analyses
Each model was used to simulate men and women who were
born in 1950 from age 45 (calendar year 1995) to death or age 90,
under 576 programs and 2 reference scenarios (a no screening
scenario and a scenario with a maximum of 3 screens; Table 2).
Screening programs varied according to five criteria: age to start
screening (45, 50, 55, 60); age to stop screening (75, 80, 85); screen
frequency (every 1, 2, or 3 years); minimum number of pack-years
of cigarette exposure (10, 20, 30, 40); and (for former smokers)
maximum years since quitting (10, 15, 20, 25). We refer to
programs using shorthand for Periodicity (A, annual, B, biennial,
or T, triennial), Start Age - Stop Age - Minimum Pack-Years -
Maximum Years Since Quit. For example A55-75-30-15 repre-
sents starting screening at age 55 years and ending screening at age
75, for individuals with a minimum smoking history of 30 pack-
years, and a maximum years since quitting of 15 years. This
program, which we refer to as ‘NLST eligibility’ is similar to the
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(a maximum of 21 screens are possible from ages 55 to 75).
As individuals age, their accumulated pack-years or years since
quitting may change. In this analysis, the models assessed eligibility
annually; to be screened at a specific age within the qualifying age
range, an individual also had to meet both the pack-years and the
years-since-quitting criteria. Thus lighter smokers may not begin
screening at the start age and former smokers may cease screening
prior to the stop age.
All simulations were performed assuming idealized, perfect
screening adherence for eligible individuals and smoking cessation
was assumed to be unaffected by screening results.
For the biennial and triennial programs, the frequency of
screening exams was changed while retaining each model’s natural
history parameters, which simulate the underlying progression of
disease.
Model M generated a second set of results that added operative
candidacy (i.e. healthy enough for curative surgery) as an eligibility
criteria for screening and reduced rates of operative candidacy in
older patients (Part A in File S1) [16].
Outcome Metrics
For each program, each model generated counts of screening
exams and lung cancer deaths avoided relative to no screening,
separately for males and females. All events are ‘per person in the
population’ rather than ‘per person screened’ because programs
defining eligibility based on smoking history may screen similar
proportions of the population but screen dissimilar people, even for
identical starting and stopping ages. Counts of screening exams
excluded follow-up and incidental CT exams. Counts of deaths
avoided per screening scenario were expressed as the proportion of
the (within-model) maximum possible deaths avoided from any of
the screening programs evaluated.
In this analysis, we sought to formally represent the tradeoffs
between maximizing the benefits (here, lung cancer deaths
avoided) accruing to a specific screening program while simulta-
neously minimizing the harms (here, the numbers of screening
exams required to avoid the lung cancer deaths). One way to
compare alternative programs that represent different tradeoffs is
to generate an ‘‘efficiency frontier’’. Each model generated
efficiency frontiers for each sex that connected the screening
programs that prevented the most deaths for each possible value of
the number of CT screens. (Note that our definition of efficiency is
not equivalent to identifying the lowest ratio of screens per death
avoided. As screening intensity increases, the number of screens
per death avoided will increase, but among programs with similar
numbers of screens, some [the most efficient] will prevent more
deaths.) For each model’s results, we generated a rank score (decile
of distance [17] from the model’s frontier) for each program not on
the frontier (Part B in File S1). Programs on or closest to the
frontier (first three deciles) as predicted by at least 3 models were
identified for males and females separately. Programs that were in
both male and female lists were defined as consensus programs.
For each consensus program, we combined counts per 100,000
persons from males and females and calculated the mean
predicted counts of lung cancer cases, lung cancer deaths, life
years, and screening CT exams performed. We calculated the
percent of the cohort receiving at least one screening exam and the
number of persons ever screened per lung cancer death avoided
(number needed to screen, NNS).
A secondary set of consensus programs for which the benefit
(i.e., the y axis) was measured as life years saved (with the x axis
remaining counts of CT screens) was also identified, using the
identical steps as above.
Results
Using eligibility criteria like those in NLST, neither 3 annual
screens (A62-64-30-15) nor 21 annual screens (A55-75-30-15)
appears on the frontier for any model (Figure 1 and Figure S7 in
File S1). There was variability among the models with respect to
the effects of the smoking criteria on distance from the frontier, but
consensus was clear regarding age: compared with A55-75-30-15,
all models placed A55-85-30-15 closer to (or on) the frontier,
indicating that continuing screening to older ages was more
efficient than stopping at age 75. Conversely, initiating screening
at younger ages (A45-75-30-15) was farther from the frontier (less
efficient). Less-frequent (B55-75-30-15) screens provided fewer
benefits, as did increasing the pack-year minimum (A55-75-40-15).
The most intensive annual program (A45-85-10-25) was the upper
right of the frontier for all models.
We identified 120 consensus programs. Of these, 119 had a
stopping age of 80 or 85 (Figure 2, Table S2 in File S1, and Figure
S8 in File S1). Across the 120 consensus programs, the average
start age (54.8 y) and the average minimum pack-years (27.1) were
close to the NLST criteria but the average maximum years since
quit was higher (19.9 y). For all models (Figure 3), the 120
consensus programs are close to the model’s own frontier.
Results from a selected subset of 41 (every third, sorted by
percent ever screened) consensus programs are provided in Table 3
Table 2. Screening programs evaluated.
Program Characteristic Values # of Combinations
Frequency of screening Annual, every 2 years, every 3 years 3
Age to begin screening 45, 50, 55, 60 4
Age to end screening 75, 80, 85 3
Minimum PY for screening 10, 20, 30, 40 4
Maximum YSQ for screening 10, 15, 20, 25 4
Total (including 2 reference programs) 578
PY, pack-years; YSQ, years since quitting. Reference programs: no screening and an approximation of the National Lung Screening Trial design (at age 62, 3 annual
screens for smokers with .=30 PY, and ,=15YSQ).
All screening programs simulated U.S. cohorts born in 1950. For individuals meeting the pack-year and (for former smokers) years since quitting cutoffs, the first screen
occurs at the beginning age and last screen occurs at the ending age. Programs are labeled as follows: Frequency (Annual, Biennial, Triennial) Age Start-Age Stop-
minimum PY- maximum YSQ. As an example, B55-85-20-15 corresponds to biennial screening starting at age 55, ending at age 85, subject to a minimum pack-year
history of 20 and a maximum years since quitting (for former smokers) of 15.
doi:10.1371/journal.pone.0099978.t002
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PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e99978(mean and SD of results from the five models). Between 11% and
40% of the cohort was screened, requiring between 43,000 to over
920,000 CT screens per 100,000 persons (Table 3). The models
predicted an average of 3,719 lung cancer deaths per 100,000 in
the no screening scenario (SD 820.43; Figure S6 in File S1). Per
100,000 persons, the 41 consensus programs would avoid between
153 and 846 lung cancer deaths and save between 1,883 and 9,851
years of life, relative to no screening, and the mean predicted NNS
varied from 34.5 to 94.2.
Based on results from one model (M), reducing the proportions
of older individuals screened (due to ineligibility for surgical
resection) resulted in fewer CT screens and fewer lung cancer
deaths avoided (13.3% and 14.8%, respectively, across the
consensus programs), but programs that extended screening to
ages 80 and 85 remained on the efficiency frontier (Figure S9 in
File S1).
When the benefit of screening was measured as life years saved
rather than lung cancer deaths avoided, the second set of
consensus efficient programs had younger average start and stop
ages (49.5 y and 80.9 y, respectively) but similar average minimum
pack-years and maximum years since quit (Table S3 in File S1).
Discussion
Five independent models ranked 576 lung cancer screening
programs by weighing one metric of their potential benefits (lung
cancer deaths avoided) against one measure of harms or resource
use (counts of CT screening exams) in the US cohort born in 1950.
The models had been previously calibrated to multiple endpoints
in NLST,
12 but heterogeneity in the underlying model structures
and assumptions yielded heterogeneous predictions for absolute
numbers of lung cancer deaths avoided when extrapolating
Figure 1. Systematic variation of reference screening program
A55-75-30-15. Vertical axis normalized so that 1.0 represents within-
model prediction of lung cancer deaths avoided with most intensive
screening program (A45-85-10-25); values not directly interpretable as a
hazard ratio. Compared to annual screening of individuals aged 55 to
74 with at least 30 pack-years of cigarette smoking and who quit with in
the last 15 years (reference, x) a program of continuing annual
screening to eligible individuals up to age 85 (+) was closer to the
efficiency frontier. Results from one model shown; see Figure S7 in File
S1 for results from all five models.
doi:10.1371/journal.pone.0099978.g001
Figure 2. Exemplar model showing consensus programs. Vertical axis normalized as in Figure 1. Consensus programs were the 120 (out of 576
evaluated, see Table 2) that five models ranked as most efficient. Only a single consenus strategy (the single orange +) had a stop age of 75. The
remaining consensus strategies continued screening of individuals meeting the smoking eligibility criteria to ages 80 (aqua) or 85 (purple). Annual
screening (triangles) provided greater benefits (i.e., averted more lung cancer deaths) than triennial (+) or biennial (squares). Results from one model
shown; see Figure S8 in File S1 for results from all five models.
doi:10.1371/journal.pone.0099978.g002
Benefits of Lung Cancer Screening Programs
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e99978Figure 3. Normalized plots from all models showing consensus programs. Shown are efficiency frontiers for all 5 models, with the 120
consensus programs marked. All vertical axes are normalized to within-model predictions, as in Figures 1 and 2.
doi:10.1371/journal.pone.0099978.g003
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PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e99978beyond the trial data. A key finding of our analysis was that despite
differences in absolute benefits across the models, the ranking of
programs was consistent; while accounting for the heterogeneity in
model predictions, we were able to identify a set of consensus
efficient programs. Annual screening with eligibility based on
NLST criteria (beginning at age 55, continuing to age 75 for
current and former smokers with a minimum of 30 pack-years and
less than 15 years since quitting) was not among the programs on
the efficient frontier of any of the five models. Results from all
models showed that programs that extended the screening age
beyond 75 prevented more lung cancer deaths for relatively few
additional screens. Note that in our modeling, the stopping age for
a program was the last screen for any individuals who still met the
smoking cutoffs, and not the last year to be invited to begin a
screening program. In the NLST which had an upper eligibility
age of 74 years, individuals were as old as (77 or, rarely, 78) at the
third screen. Our finding that programs that screened eligible
individuals past age 75 years were efficient was unchanged when
more older patients were ineligible for screening due to
comorbidities that categorized them as non-operative candidates
(based on results from one model) or when life years saved was
substituted for the measure of benefit. While in other cancers (e.g.
breast and colorectal) screening is not generally recommended
beyond age 75 and not generally recommended every year, in lung
cancer annual screening to older ages can be beneficial because:
(1) the age-specific incidence curve for lung cancer is quite steep,
and (2) the high lethality of the disease makes early detection
worthwhile, even among individuals with a somewhat modest life
expectancy. It is also important to note that had we defined life
years saved (instead of lung cancer deaths avoided) as the measure
of benefit, one could logically predict that strategies with younger
stopping ages would be more likely to emerge as ‘consensus
efficient’.
Our predicted NNS for A55-80-30-15 varied across models,
ranging from 19.8 (Model F) to 100.5 (Model M), but all were
below published estimates of NNS for only 3 screens of (256) [18]
and closer to published NNS for mammography (95) or FOBT
(roughly 130) for healthy 50 year-olds [19].
For consensus programs with screening until age 80, between
11% (for the least frequent programs with strictest eligibility, e.g.,
T60-75-40-10) and 40% (for the annual programs with more
inclusive eligibility, e.g., A45-80-10-25) of the cohort born in 1950
would be screened at least once after age 45. Although not directly
comparable to earlier estimates that 6% (8.7 million people) of US
adults over 40 would meet the NLST eligibility cutoffs for lung
cancer screening each year [20,21], our estimate of 11% of
individuals seems reasonable.
We identified a set of consensus efficient programs rather than a
single optimal strategy, because the efficiency frontiers did not
identify a consensus inflexion point at which additional screens
provided diminishing benefits. The least intensive programs at the
lower left of the frontiers (Figure 2) may be less attractive, however,
since annual screening consistently prevented more lung cancer
deaths than did triennial or biennial programs. The most-intensive
screening programs, on the other hand, will lead to more
accumulated harms (radiation exposure from additional imaging
examinations, overdiagnosis, invasive biopsies) and costs.
Screening programs cannot be evaluated in isolation from the
follow-up algorithm. In the NLST, an average of 24% of
individuals in a given round of screening (CT arm) had results
requiring some follow-up, but the trial did not specify a follow-up
regimen, leaving open the question of the optimal regimen for
individuals with positive screens, most of whom are healthy [4,22].
In models (E, F, U) that used implicit follow-up algorithms based
on the experience of participants in the NLST, extrapolating the
rate of follow-up to less frequent screening programs was
dependent on the assumption that the rates of follow up exams
and early detection of lung cancers (defined in the NLST and
models E, F, and U as ‘screen-detected’ even if first seen on a
follow-up exam) would not change. In the models (M, S) that
explicitly modeled follow-up programs based on size, follow-up
exams could change the timing of detection of a lung cancer, but
the assumptions used here for frequency of follow-up imaging may
not be representative of eventual practice patterns.
Several limitations of our analysis are important to note. The
models do not simulate non-lung cancer incidental findings (e.g.,
coronary artery calcification, AAA, or other malignancies), so our
results do not include potential benefits (or harms) due to their
detection and treatment. There are few data to predict adherence
patterns for lung cancer screening [20,23], and many possibilities
to model. We conducted an idealized analysis with the goal of
informing guidelines and did not consider that individuals will self-
select for participation in screening based on their comorbidities,
specific smoking history, or family history, as observed in screening
trials [24,25]. It will be important to monitor how lung cancer
screening is implemented in community settings (including
recruitment, participation, positive screen evaluations, diagnosis,
referral for treatment), and modeling can suggest the most
important leverage points to optimize the process. Definitive
evidence on the relationship between smoking cessation and
NLST screening results was not available in time for our analyses.
Based on limited data with non-standardized definitions of ‘quit’
[26–29] and the PLCO Trial, which found no correlation between
CXR screening result and smoking behavior [30], we assumed
screening did not affect background smoking patterns.
Efficient screening programs might differ in populations with
different smoking patterns or other-cause mortality risks than the
cohort we simulated. To simplify the comparison of hundreds of
programs, we performed our analyses in a single birth cohort and
did not estimate total lung cancer deaths avoided in the US [31].
Our requirement that individuals meet all eligibility criteria
(including years since quitting) was transparent and is a step
towards risk-based screening criteria (our models account for
decreasing risks of death from lung cancer and other causes after
quitting), but may not reflect guidelines, which typically define
eligibility to begin screening. Future analyses to examine programs
that define eligibility based on risk models will require that the
models and population input files include additional characteristics
(e.g., BMI, education) that go beyond age and smoking exposure
[32–36]. We did not incorporate increases in operative mortality
rates by age, or special clinical considerations individual to a
particular patient.
Although the rankings of programs were consistent across
models, uncertainty in absolute numbers of lung cancer deaths
avoided (and life years saved) remained, due to variation in the
underlying assumptions regarding unobserved disease processes
[37]. Underlying the differences across models in predicted
absolute benefits is a variation in the predicted future number of
lung cancer cases in the absence of screening (Figure S5 in File S1).
Essentially, our consortium of 5 models served as a sensitivity
analysis on model structure and demonstrated that even when
model heterogeneity was specifically taken into account, the
models identified similar efficient programs (i.e., the consensus set).
Our results highlight tradeoffs between preventing greater
numbers of lung cancer deaths and the additional screening exams
required. Guidelines for screening also consider tradeoffs in gains
in life expectancy and important harms, including invasive
biopsies for benign disease, overdiagnosis, and lung cancers
Benefits of Lung Cancer Screening Programs
PLOS ONE | www.plosone.org 9 June 2014 | Volume 9 | Issue 6 | e99978related to radiation from diagnostic imaging examinations [10].
Difficulties with estimating population effects of screening include
the potential for concurrent smoking cessation programs to
augment the benefits from screening, and the heterogeneity of
the radiation dose attributable to a given CT exam, which could
vary as much as 10-fold depending on the size of the patient, the
generation of scanner, and the protocol in use at the clinical setting
[38]. All smokers, whether undergoing screening or not, should
receive cessation assistance and be encouraged to quit [39].
Supporting Information
File S1 Supporting figures and tables. Figure S1,
Prevalence of smoking by age in 1950 birth cohort.
Summary of shared input data (used by all 5 models) on smoking
patterns for the US cohort born in 1950. Prevalence shown is
estimated in the absence of lung cancer mortality. Version 1.0 of
the Smoking History Generator (SHG) refers to published data
through 2000 (Anderson, et al.), and version 1.5 supplies the 1950
birth cohort used for this analysis with data through 2009 and
projections past 2009. Figure S2, Other-cause mortality, by
smoking quintile, in 1950 birth cohort. These curves show
the other-cause (non-lung cancer) mortality for never smokers and
for current smokers by smoking quintile (Q, of cigarettes per day)
for the male birth cohort of 1950, out to age 99. Former smokers
are intermediate to current and never smokers. There is a similar
plot for females. These were shared inputs used by all the models.
Note that the rates of non-lung cancer mortality represent the US
population, not trial (NLST or PLCO) participants. Figure S3,
Prevalence of smoking by age in 1950 birth cohort.
Output from one model showing smoking prevalence by age
(calendar year), in a no screening scenario. Proportions of current/
former/never smokers are in the presence of lung cancer mortality
as well as all-cause mortality. Figure S4, Prevalence of
smoking by age and pack-years in 1950 birth cohort.
Output from one model showing smoking prevalence by category
of pack-year and age. The proportion of the cohort by age that has
accumulated the specified number of pack-years in the presence of
lung cancer mortality and other-cause mortality. Figure S5,
Incidence, no screening scenario, output from all
models. For predictions past observed SEER data (over age
60) there are no observed data, but we used an age-period-cohort
model to project past observed years (‘Projected’ red double line in
plots below), which shows that the models are most divergent after
age 85, when SEER data become most sparse. We cannot strictly
compare incidence to that in prior birth cohorts since smoking
patterns are dissimilar, and incidence varies by cohort. Figure S6,
Mortality, no screening scenario, output from all
models. The vertical line at age 90 indicates age at which all
event counts (screens, deaths and deaths averted, and life years
gained) were truncated for the analyses reported here. Although
the models ranked programs similarly, there was variability in the
total numbers of predicted lung cancer cases, deaths, and therefore
lung cancer deaths prevented. The differences in rates in the no
screening scenario in large part explains the predicted differences
between models. The four models (E, F, S, and U) which use two-
stage or multi-stage clonal expansion models have more similarly
shaped curves than the fifth model (M), which does not use a
clonal expansion component (see Table S1 in File S1). Figure S7,
Results from all models analogous to Figure 1 in article.
Figure S8, Results from all models analogous to Figure 2
in article. Figure S9, Secondary results with reduced
operative candidacy with age. The dashed line denotes the
efficiency frontier in the main analysis. Table S1, Additional
Detail on Models. Table S2, Complete List of 120
Consensus Efficient Scenarios. Table S3, Comparison
of Consensus Efficient Scenarios Identified Using Life-
years Saved or Lung Cancer Deaths Avoided as Measure
of Benefit.
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